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Abstract: We recently described a structurally novel series of negative allosteric modulators 
(NAMs) of the dopamine D2 receptor (D2R) based on thieno[2,3-d]pyrimidine 1, showing it can be 
structurally simplified to reveal low molecular weight, fragment-like NAMs that retain robust 
negative cooperativity, such as 3. Herein, we report the synthesis and functional profiling of 
analogues of 3, placing specific emphasis on examining secondary and tertiary amino substituents at 
the 4-position, combined with a range of substituents at the 5/6-positions (e.g. aromatic/aliphatic 
carbocycles). We identify analogues with diverse pharmacology at the D2R including NAMs (19fc) 
with sub-µM affinity (9h) and, surprisingly, low efficacy partial agonists (9d and 9i).  
 
Keywords: negative allosteric modulators, dopamine D2 receptor, thieno[2,3-d]pyrimidines, 
NAMs, agonists. 
  
1. Introduction 
The D2R is a class A G protein-coupled receptor (GPCR) implicated in the pathophysiology and 
treatment of a number of central nervous system (CNS) disorders, including schizophrenia (SCZ). 
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As such, drugs targeting this receptor have traditionally targeted the orthosteric site - where the 
endogenous ligand DA binds. Clinically used antipsychotic drugs (APDs) targeting this site act as 
D2R antagonists or low efficacy partial agonists, and are termed typical or atypical APDs based on 
their propensity to cause extrapyramidal side effects. Unfortunately, the efficacy of these drugs is 
largely limited to the positive symptoms of this disorder. Typical APDs are associated with extra-
pyramidal motor symptoms (EPS) and hyperprolactinaemia, which are mediated by blockade of 
D2R signalling in the nigrostriatal and tuberoinfundibular DA pathways, respectively.1-6 Atypical 
APDs show a reduced incidence of EPS, but display other off-target side-effects mediated through 
the interaction with other aminergic receptors, including metabolic disorders and weight gain.7  
Alternative approaches to target the D2R have emerged via the identification of homo- and 
heterodimeric complexes.8 Such complexes in specific tissues may provide novel pharmacological 
targets for compounds with distinctive functional profiles and improved therapeutic windows.9-11 
Another proposition which entails targeting binding sites topographically distinct to the orthosteric 
site of GPCRs might also be advantageous. Negative allosteric modulators (NAMs) of the D2R may 
represent a safer therapeutic approach for the treatment of SCZ symptoms. A D2R NAM with 
limited negative cooperativity with DA may display antipsychotic efficacy but avoid EPS through 
partial blockade of the D2R akin to the action of atypical partial agonist APDs such as 
aripiprazole.12 Furthermore, as a NAM will allow DA to bind, the spatiotemporal pattern of DA 
signalling is more likely to be maintained. Finally, NAMs may display greater selectivity for the 
D2R over other targets via the targeting of less evolutionarily conserved sites and consequently 
reduced off target toxicities. Drug-like (NAMs) of DA receptors have recently been identified 
including the scaffold that is the focus of the present study.13-19 
Our previous study described the pharmacological validation of a virtual ligand screen hit 
(1, Figure 1), confirming that it binds with low µM functional affinity and exerts its effect via 
negative allosteric cooperativity, primarily by modulation of dopamine signalling efficacy.18 Based 
on the scaffold of 1, we synthesised a small library of structural analogues to further understand key 
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molecular features that were responsible for changes in affinity and negative allosteric 
cooperativity. Of several promising analogues identified, 2 (Figure 1) maintained low µM affinity 
(KB = 1.92 µM) and significantly attenuated DA signalling efficacy (β = 0.001). This compound was 
devoid of the morpholinomethyl moiety present on 1, and also incorporated replacement of the ((3-
trifluoromethyl)phenyl)amino- substituent with an N,N-diethylamino motif. In addition to this, our 
previous work focused on assessing various substituents at the 5/6-positions (e.g. phenyl, 
cyclohexyl) in place of the fused cyclohexane system. Moreover, we discovered that the scaffold 
could be structurally simplified, to reveal a low molecular weight fragment-like starting point that 
maintained µM affinity and negative cooperativity (MW = 207, KB = 4.56 µM, β = 0.13) (3, Figure 
1). Thus, we identified an appropriate starting point for further structural interrogation and 
elaboration of the core scaffold using 2 and 3 as our lead compounds with the aim to identify higher 
affinity NAMs. 
 
Fig. 1. Promising structural analogues of 1 arising from a preliminary structure-activity 
relationship (SAR) investigation. Compound 1 was identified from a virtual ligand screen and 
formed the basis of our previous SAR study. Compound 2 significantly attenuates DA signalling 
efficacy at a concentration of 10 µM (KB = 1.92 µM, β = 0.001). Compound 3 retains negative 
allosteric cooperativity despite being a structurally simplified fragment-like analogue (MW: 207, KB 
= 4.56 µM, β = 0.13) of 1. 
 
To this end, we sought to investigate the influence of varying the nature (both aliphatic and 
aromatic) of the 4-amino moiety of 2 (series 1, Figure 2). In addition, a second series of compounds 
was designed to further explore the effect of 5/6-thiophene substitution with respect to altering 
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functionality at the 4-position (series 2, Figure 2). This would permit further refinement of the 
structural determinants of D2R affinity and negative cooperativity. Through the parallel synthesis of 
an additional thirty-seven structural analogues of 2, we have identified molecules that exert a range 
of modulatory behaviour including, surprisingly, derivatives that display agonism. To confirm a 
D2R-mediated mechanism of action, all compounds with agonist profiles together with selected 
NAMs were assessed for their ability to modulate our functional readout in the absence of the D2R. 
 
Fig. 2. Areas of structural modification conducted during SAR investigation of 2. 
 
2. Chemistry 
The synthesis of all compounds generally followed established methods for the synthesis of 1 and 
other related compounds previously reported by our research group.18 Each compound detailed in 
this study was easily accessed in four steps (schemes 1-3). Briefly, Scheme 1 depicts the synthesis 
of selected analogues (9a-j), beginning with Gewald20 chemistry to facilitate the one-pot 
construction of the ethyl 2-amino-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylate (5),18 
followed by cyclisation with formamide (6) to afford the corresponding 5,6,7,8-
tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone (7).18 POCl3 was employed to convert pyrimidinone 
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7 to the corresponding key intermediate chloropyrimidine 8,18 followed by nucleophilic aromatic 
substitution (SNAr) with the desired amine, in the presence of Hünig’s base in propan-2-ol. This 
methodology afforded compounds 9a-j in high purity after a simple work-up and/or 
chromatography. 
 
Scheme 1. Synthesis of analogues of 2 modified at the 4-positiona 
aReagents and conditions: (i) S8, cyclohexanone, morpholine, rt, ~18 h, 81%; (ii) 170 °C, 12 h, 85%; 
(iii) POCl3, DMF(cat.), toluene, 4 h, 68%; (iv) amine, DIPEA, i-PrOH, reflux, 1-3 h, 68-88%; (v) 9j, 
TFA, DCM, rt, 4 h, 96%. 
 
2.1. Analogues of 2 varied at the 4-(N,N-diethylamino) substituent 
Compound 2 was originally synthesised as an analogue of 1 to observe the effect of simultaneously 
removing the morpholinomethyl moiety whilst incorporating a 4-(N,N-diethylamino) group in in the 
context of retaining the  tricyclic structure of the 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine. As this molecule was found to be a potent NAM of DA efficacy at the D2R, an 
additional series of compounds was synthesised to investigate further changes to the 4-position of 
the pyrimidine ring (Scheme 1). Preliminary modifications included incorporating 6-membered 
secondary aromatic and aliphatic amino substituents (e.g. anilino (9a) and cyclohexylamino (9b) 
together with 6-membered cyclic aliphatic tertiary amine moieties, including piperidino (9c), 
morpholino (9d) and piperazino (10),  followed by the smaller pyrrolidino (9e) to assess the 
influence of a five-membered cyclic aliphatic system. The piperazino analogue 10 was obtained via 
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the SNAr reaction between commercially available N-Boc piperazine and 8 under microwave 
conditions as outlined previously (Scheme 1) to afford 9j as a crystalline solid requiring no further 
purification. Standard trifluoroacetic acid-mediated N-Boc de-protection followed by an alkaline 
work-up furnished 10. This molecule is unique relative to its counterparts in that it will impart a 
positive charge at physiological pH. Moreover, we investigated both monocyclic (cyclopropylamino 
(9f), cyclopropylmethylamino (9g), cyclobutylamino (9h)) and acylic aliphatic secondary amine 
substituent (tert-butylamino (9i)). The tert-butylamino substituent was installed to assess the effect 
of an acylic aliphatic secondary amine as a comparison to N,N-diethylamino. These syntheses were 
all achieved using chemistry as previously outlined (Scheme 1), and successfully afforded ten 
analogues (9a-i, and 10) in yields varying from 68-88% following SNAr of 8 with the appropriate 
amine.  
 
2.2. Fragment analogues of 3 
We previously reported a low molecular weight fragment (N,N-diethylthieno[2,3-d]pyrimidin-4-
amine, (3)) that retains low µM functional binding affinity and negative allosteric cooperativity at 
the D2R (KB = 4.56 µM, β = 0.13, Figure 1).18 This molecule was originally synthesised using a 
deletion strategy to examine the effect of switching from a 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine to the corresponding thieno[2,3-d]pyrimidine scaffold, in conjunction with 
incorporating a tertiary aliphatic amine at the 4-position. As such, we generated two additional 
analogues of 3 bearing 4-cyclopropylamino and 4-cyclobutylamino substituents. Their synthesis is 
depicted in Scheme 2 and begins with the construction of ethyl 2-aminothiophene-3-carboxylate 
(12)18 using ethyl cyanoacetate (4) and 1,4-dithiane-2,5-diol (11) under modified Gewald 
conditions. Refluxing 12 in neat formamide afforded the corresponding pyrimidinone (13)18 in good 
yield. Subsequent chemistry as outlined previously included deoxychlorination to give 14,18 
followed by SNAr with cyclopropylamine or cyclobutylamine to afford the corresponding analogues 
15a and 15b, respectively.  
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Scheme 2. Synthesis of Thieno[2,3-d]pyrimidine Analogues of 2a 
 
aReagents and conditions: (i) Et3N, DMF, 45 °C, 0.5 h, 55%; (ii) formamide (neat), 170 °C, 12 h, 
76%; (iii) POCl3, DMF(cat.), toluene, 100 °C 4 h, 77%; (iv) amine, DIPEA, i-PrOH, 100 °C, 1-3 h, 
76% (15a), 79% (15b). 
 
2.3. Single modifications to the 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine moiety of 2 
whilst varying the nature of the 4-substituent 
Our previously reported SAR study of 1 focused on structural modifications to the fused 
cyclohexane system, including switching from a 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine to the corresponding thieno[2,3-d]pyrimidine, 5- and 6-aryl substitution, 5- and 6-
cyclohexyl substitution, 5,6-dimethyl substitution, as well as incorporation of fused cyclopentane, 
cycloheptane, and cyclooctane systems.18 These structural modifications were mostly employed in 
the presence of a 3-(trifluoromethyl)anilino substituent at the 4-position, and a 2-morpholinomethyl 
substituent. Only the fused cyclopentane and the 6-cyclohexyl modifications preserved the allosteric 
pharmacology seen with this scaffold, while the other structural modifications rendered the 
corresponding molecule functionally inactive. This study, however, had demonstrated the 
encouraging effects of incorporating N,N-diethylamino, cyclopropylamino, or cyclobutylamino to 
the 4-position of the pyrimidine core, increasing functional affinity as well as maintaining the 
magnitude of negative allosteric cooperativity whilst bearing the fused cyclohexane system (Series 
1, Figure 2). To this end, we wanted to evaluate combining the structural modifications to the 
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thiophene, whilst concurrently incorporating the aforementioned 4-amino substituents (Series 2, 
Figure 2). These compounds would further refine the SAR and provide insight into the design of 
further high affinity NAMs. These modifications are depicted in Figure 2 and their chemical 
synthesis is outlined in Scheme 3. All compounds were accessed using established chemistry as 
detailed in our previous work, beginning with construction of the appropriate thiophene via 
Gewald20 chemistry (16a-h),18 formation of the corresponding pyrmidinones (17a-h)18 and 
chloropyrimidines (18a-h),18 followed by SNAr with the appropriate amine to furnish a further 
twenty-four analogues (19aa-hc).  
 
Scheme 3. Synthesis of Functionalised Analogues of 2a 
 
aReagents and conditions: (i) aldehyde or ketone, S8, morpholine, rt 12-24 h, 38-84%, 16a-h; (ii) 
formamide, 170 °C, 12 h, 75-85%, 17a-h; (iii) POCl3, DMF(cat.), toluene, 100 °C, 3-5 h, 77-91%, 
18a-h; (iv) amine, DIPEA, i-PrOH, MWI, 1-3 h, 71-93%, 19aa-hc. 
 
3. Pharmacology 
3.1. Functional and off-target analyses of analogues of 2 using a BRET biosensor for cAMP 
To measure the effect of these compounds upon the functional response of the D2R when stimulated 
by DA we made use of a BRET biosensor of cAMP. This assay measures inhibition of forskolin-
stimulated cAMP accumulation through activation of the long isoform of the human D2R (hD2LR) 
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stably expressed in FlpIn CHO cells and provides a robust measurement of D2R Gαi/o activation to 
allow estimates of functional binding affinities and quantify the magnitude of modulatory effects.18 
Application of an operational model of allostery to the DA concentration-response data obtained in 
the presence and absence of increasing concentrations of our test compounds yielded an estimate of 
their affinity for the unoccupied receptor (KB), cooperativity with DA affinity (α) and modulation of 
DA efficacy (β), plus the intrinsic efficacy of the allosteric ligand (τB).21 Values of α or β < 1 
signify negative modulatory effects with DA, and values of α or β > 1 signify positive modulatory 
effects. Logarithms of affinity and cooperativity values are normally distributed, whereas the 
absolute values (antilogarithms) are not.22 Thus, all interpretation of the SAR described below 
(Tables 1-3) refer to the logarithmic values. For ease of interpretation, however, the allosteric 
parameter antilogarithms are also highlighted in the main text for selected key analogues. As 
reported previously, the lead compound 2 acted as a NAM at the D2R, with low µM functional 
affinity (KB = 1.92 µM, Table 1).18 The depression in the DA dose-response curve caused by 
increasing concentrations of 2 is characteristic of the action of a NAM of agonist efficacy and β was 
fixed to 0.001 when fitting these data to signify high negative cooperativity (Figure 3A, Table 1).  
To our surprise, we identified molecules based on this NAM scaffold that now appear to 
display agonism. It was important, then, to confirm that these effects are D2R mediated. Luciferase 
assays may identify false positive ‘hits’ through a variety of mechanisms, for example, by inhibition 
of the luciferase enzyme.23-25 To allow us to discriminate between D2R-mediated activities and any 
non-specific effects (Supplementary Figure 1), all compounds observed to display D2R agonism in 
our cAMP assay were selected for further analysis (9c-d, 9i, 15a-b, 19ac, 19ca, 19da, 19db, 19dc, 
19ec, and 19ha). In addition, a number of other compounds were selected, namely the parent NAMs 
1 and 2, together with NAMs 9h, 19bb, 19fb, and 19fc. We measured their ability to modulate the 
BRET signal in FlpIn CHO cells transfected with the CAMYEL biosensor,26 but not expressing the 
D2R. All compounds were measured up to a concentration of 100 µM in both the presence and 
absence of forskolin (10 µM). DA (10 µM) was also used as a control. Two compounds (9c, 19ca) 
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were found to display effects independent of any action at the D2R. Importantly, the original VLS 
hit (1), representative NAMs (2, 9h, 19bb, 19fb, and 19fc), as well as all other agonists exert an 
effect dependent on the presence of the D2R. 
 
4. Results and discussion 
4.1. Functional analysis of 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine analogues of 2 
We first examined the effect of introducing various monocyclic/acyclic aliphatic amines to the 4-
position of the core scaffold whilst still bearing the fused cyclohexane system. This was based on 
our finding that 2, bearing a 4-(N,N-diethylamino) substituent, displayed high negative 
cooperativity. As outlined in Table 1, anilino (9a) and cyclohexylamino (9b) substituents rendered 
the corresponding analogues functionally inactive. Substitution with the smaller cyclopropylamino 
substituent (9f) resulted in a modest increase in functional affinity (KB = 0.88 µM) and maintenance 
of a negative modulatory effect on DA efficacy (β = 0.03, Figure 3C). The cyclopropylmethylamino 
analogue (9g) maintained a functional affinity (KB = 1.19 µM) similar to that of 2, but more modest 
modulatory effects upon dopamine efficacy (β = 0.29). Introduction of a cyclobutylamino 
substituent (9h) not only maintained this negative modulatory action, but acted to increase affinity 
(KB = 0.57 µM, α = 0.19, β = 0.22, Figure 3D).  Conversely, the tert-butylamino analogue (9i) lost 
~50-fold functional affinity relative to 2 (KB = 92.5 µM), but now, surprisingly, exerted agonism (τB 
= 0.91). It is interesting to note that introduction of the tert-butylamino moiety (9i) abolished 
negative cooperativity, whereas the N,N-diethylamino substituent (2) confers a high degree of 
negative allosteric modulatory effects upon dopamine efficacy. These data demonstrate that the ring 
size and nature of the substituent at the 4-position are crucial for both affinity and negative 
modulatory action. We found that larger 6-membered cyclic substituents bearing secondary amines, 
both of aromatic and aliphatic nature, are not tolerated, whereas three- and four-membered cyclic 
substituents (cyclopropylamino and cyclobutylamino, respectively) increase affinity and maintain 
modulatory properties in conjunction with the fused cyclohexane system. We next examined the 
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effect of substituents bearing tertiary amines by incorporating various cyclic amines. The piperidino 
analogue (9c) decreased the functional affinity by 10-fold (KB = 59.3 µM), and was devoid of any 
modulatory effect on DA but, surprisingly, appeared to exert an intrinsic response in its own right. 
However, our assay using FlpIn CHO cells that do not express the D2R revealed that this is effect is 
most likely an off target effect (Supplementary Figure 1). The morpholino analogue (9d) further 
decreased the functional affinity, some ~65-fold (KB = 126 µM), but also displayed agonism (τB = 
1.66) with negligible modulatory action on DA an effect that required the expression of the D2R 
(Figure 3B). Interestingly, isosteric replacement of the morpholine O with NH to give the 
piperazino analogue (10), significantly changed the pharmacology as concentrations of 10 caused 
no decrease in DA maximal response, whilst acting to cause a limitless rightward shift in the DA 
dose-response curve. Such a pattern could be consistent with either very high negative cooperativity 
with DA affinity, or conversely, a competitive mode of action. Accordingly, these data could also 
be fit with a model of competitive antagonism (pA2 = 4.67 ± 0.09, Schild slope: 1.06 ± 0.12, Figure 
3E). If this molecule is indeed competitive with DA we speculate that the presence of the piperazino 
ionisable nitrogen atom at physiological pH may potentially confer greater affinity for the 
orthosteric binding pocket, consequently converting the pharmacology from allosteric to 
competitive. Decreasing the ring size by one carbon relative to 9c to give pyrrolidine analogue (9e), 
maintained functional affinity (KB = 4.23 µM), and displayed robust negative allosteric modulatory 
effects upon DA efficacy (β = 0.17).  
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Table 1 Functional parameters derived from cAMP BRET assay for analogues of 1 modified with 
various amines at the 4-position  
 
# R1 pKB (KB, µM)a LogτB (τB)b Log α (α)c Log β (β)d 
2 
 
5.72 ± 0.13 (1.92) = -3.0 - = -3.0 
9a 
 
nd 
9b 
 
nd 
9c 
 
4.23 ± 0.13 (59.3) NSE = 0 = 0 
9d 
 
3.90 ± 0.27 (126) -0.22 ± 0.15 (1.66) = 0 = 0 
9e 
 
5.37 ± 0.13 (4.23)  = 0 -0.76 ± 0.06 (0.17) 
9f 
 
6.05 ± 0.09 (0.88)  = 0 -1.48 ± 0.08 (0.03) 
9g 
 
5.92 ± 0.19 (1.19)  -0.06 ± 0.14 (0.86) 
-0.54 ± 0.08 
(0.29) 
9h 
 
6.25 ± 0.12 (0.57)  -0.72 ± 0.12 (0.19) 
-0.65 ± 0.07 
(0.22) 
9i 
 
4.03 ± 0.31 (92.5) -0.04 ± 0.15 (0.91) = 0 = 0 
10 
 
4.70 ± 0.09 (20.0)  = -3.0 = 0 
aEstimate of the negative logarithm of the equilibrium dissociation constant as determined in an cAMP functional assay. 
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine as determined in an 
cAMP functional assay. c Estimate of the intrinsic efficacy of the modulator. nd = inactive at concentrations up to 100 
µM. NSE, non-specific effect, compound determined to inhibit forskolin-stimulated cAMP accumulation in the absence 
of the D2R. Values represent the mean ± S.E.M. from at least three independent experiments performed in duplicate. 
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Fig. 3. Modification to the thieno[2,3-d]pyrimidine scaffold 4-substituent results in analogues 
with distinct functional effects at the hD2LR. (A) N,N-Diethylamino substitution confers negative 
allosteric cooperativity on DA signalling efficacy (2). (B) Introduction of the cyclic tertiary 
aliphatic morpholino moiety confers allosteric agonism (9d). (C, D) Introduction of 
cyclopropylamino or cyclobutylamino substituents to the 4-position in conjunction with the fused 
cyclohexane system results in analogues with sub-µM affinities that maintain negative allosteric 
cooperativity (9f, 9h). (E) Introduction of the piperazino moiety (10) converts allosteric to 
competitive pharmacology. (F) Removal of the fused cyclohexane in conjunction with a 
cyclobutylamino substituent converts allosteric pharmacology to agonism (15b). All data used in 
these graphs are detailed in Tables 1 and 2 and are presented as mean ± SEM from three 
independent experiments performed in duplicate.   
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4.2. Functional analysis of thieno[2,3-d]pyrimidine fragment analogues of 2 
We recently reported that incorporating an N,N-diethylamino substituent to the 4-position of the 
thieno[2,3-d]pyrimidine scaffold devoid of both the 2-morpholinomethyl moiety and fused 
cyclohexane systems (3), resulted in a low molecular weight fragment-like NAM of the D2R 
(Figure 1).18 As 4-cyclopropylamino and 4-cyclobutylamino substituents on the thieno[2,3-
d]pyrimidine moiety conferred sub-µM analogues with robust negative cooperativity, we further 
examined the effect of introducing these substituents to the 4-position of 3 in place of the N,N-
diethylamino functionality (Table 2). We found that introducing the cyclopropylamino substituent 
(15a) did not affect functional affinity, however caused a limitless rightward shift in the DA dose-
response curve in addition to stimulating a modest agonist response in its own right. If cooperativity 
values of α and β were constrained to -3.0 and 0, respectively, we could derive a value of affinity 
and efficacy (KB = 21.4 µM, τB = 0.22, Table 2). However, this pattern of ligand action is also 
consistent with that of a competitive low efficacy partial agonist. Furthermore, introduction of a 
cyclobutylamino substituent (15b) maintained affinity but abolished modulatory effects and 
engendered agonism (KB = 7.38 µM, τB = 0.48, Table 2, Figure 3F). Thus, relatively subtle 
structural modifications significantly change pharmacology, from compounds which negatively 
modulate the behaviour of DA from a secondary binding site, to molecules that activate the receptor 
with no cooperativity. Of note, the D2R orthosteric agonists pramipexole and sumanirole are both 
low molecular weight heterocyclic compounds bearing acyclic secondary amines.  
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
16 
 
Table 2 Functional parameters derived from cAMP BRET assay for fragment analogues of 2 with 
modifications to the 4-position  
 
# R1 pKB (KB, µM)a LogτB (τB)b Log α (α)c Log β (β)d 
3 
 
5.31 ± 0.07 (4.6)  = 0 -0.89 ± 0.04 (0.13) 
15a 
 
4.67 ± 0.08 (21.4) -0.65 ± 0.07 (0.22) = -3.0 = 0 
15b 
 
5.13 ± 0.19 (7.38) -0.32 ± 0.06 (0.48) = 0 = 0 
aEstimate of the negative logarithm of the equilibrium dissociation constant determined in an cAMP functional assay. 
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine determined in an cAMP 
functional assay. c Estimate of the intrinsic efficacy of the modulator. nd = inactive at concentrations up to 100 µM. 
Values represent the mean ± S.E.M. from at least three independent experiments performed in duplicate. 
 
4.3. Functional analysis (cAMP) of fused cyclohexane modified analogues of 2 
Our previous study revealed that incorporating various substituents (fused cyclopentane, 
cycloheptane, cyclooctane, 5- and 6-cyclohexyl, 5- and 6-phenyl, 5,6-dimethyl) to the 5-/6-positions 
of the thieno[2,3-d]pyrimidine generally rendered the corresponding analogues functionally 
inactive. However, these substituents were all previously examined on molecules also bearing 2-
morpholinomethyl and 4-(3-(trifluoromethyl)anilino) substituents. As such, we further extended our 
study to monitor the effect of incorporating favourable amino substituents (N,N-diethylamino, 
cyclopropylamino, or cyclobutylamino) onto the 4-position of the thieno[2,3-d]pyrimidine whilst 
being devoid of the 2-morpholinomethyl moiety present in 1, and bearing variation in the nature of 
substituents at the 5- and/or 6-positions (Table 3).  
4.3.1. Fused cyclopentane analogues. Our previous work revealed converting the fused 
cyclohexane system of 1 to the homologous cyclopentane system had no adverse impact on 
functional affinity, nor the degree of negative cooperativity. Molecular docking studies conducted 
using the D2R crystal structure as a template suggest that such fused hydrophobic rings interact with 
a hydrophobic subpocket located between helices V and VI formed by the residues I184ECL2, 
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V1905.39, H3946.55 (where superscript numbers refer to Ballesteros-Weinstein numbering 
system27).18,28 However, these interactions were predicted for compounds bearing a fused 
hydrophobic ring in conjunction with additional substituents located at the 2-position 
(morpholinomethyl) and 4-position (3-(trifluoromethyl)anilino). As these groups were now altered, 
we wanted to re-examine the importance of this ring system for such compounds. The N,N-
diethylamino analogue (19aa) displayed an increase in functional affinity (KB = 0.74 µM) relative to 
1 and acted to negatively modulate DA signalling efficacy (β = 0.14, Figure 4A). The 
cyclopropylamino analogue (19ab) maintained low µM affinity (KB = 6.01 µM) and similarly acted 
as a NAM of DA efficacy (β = 0.28). Conversely, the cyclobutylamino analogue (19ac) displayed a 
>15-fold decrease in functional affinity (KB = 102 µM) and acted as an agonist (τB = 0.57). These 
data were surprising as 9h, the corresponding fused cyclohexane variant of 19ac, displayed sub-µM 
affinity at the D2R and acted as a NAM of DA efficacy.  
4.3.2. Larger homologous fused rings (cycloheptane and cyclooctane). Increasing the hydrophobic 
ring size by one carbon relative to 1 was previously shown to abolish D2R activity, potentially due 
to the hydrophobic allosteric pocket failing to accommodate such extended ring sizes.18 Likewise, 
further expansion of the hydrophobic ring by one additional carbon in the presence of the 3-
(trifluoromethyl)anilino substituent also previously rendered the corresponding analogue inactive.18 
In the presence of a fused cycloheptane system devoid of the 2-morpholinomethyl substituent, 
incorporation of the 4-(N,N-diethylamino) group (19ba) similarly abolished activity. However, the 
cyclopropylamino analogue 19bb (KB = 2.96 µM, β = 0.05, Figure 4B) and cyclobutylamino 
analogue 19bc (KB = 0.91 µM, β = 0.06, Figure 4C) remained NAMs of DA efficacy at the D2R, 
with µM and sub-µM affinities, respectively. Interestingly, all cyclooctane analogues in this study 
maintained activity at the D2R. The N,N-diethylamino analogue 19ca maintained low µM affinity 
(KB = 14.5 µM) and negatively modulated DA signalling efficacy whilst exerting a slight degree of 
agonism unlike the inactive structural analogue 19ba bearing the fused cycloheptane system. 
However, this agonism proved to be a non-specific effect (Supplementary Figure 1). To our surprise 
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the cyclopropylamino analogue 19cb displayed the highest improvement in affinity seen for any 
analogue of 1 to date, some 10-fold compared to 2, coupled with robust negative modulation of DA 
signalling efficacy (KB = 0.53 µM, β = 0.10, Figure 4D). Introduction of a cyclobutylamino 
substituent (19cc) had no effects on affinity compared to 2 and this compound still acted as a NAM 
of DA efficacy (KB = 3.98 µM, β = 0.26). 
4.3.3. 5-Phenyl substituted analogues.  Installing a phenyl substituent at the 5-position of 1 in the 
presence of the 4-(3-(trifluoromethyl)anilino) substituent had previously been shown to abolish 
activity.18 Surprisingly, the N,N-diethylamino analogue (19da) not only lost >10-fold affinity, but 
caused a limitless rightward shift of the DA concentration response-curve, instead displaying weak 
agonism. From this limited set of data, however, its mode of action cannot be conclusively 
determined (i.e. allosteric agonist versus low efficacy competitive partial agonist). In order to derive 
a value of affinity and efficacy, cooperativity values of α and β were constrained to -3.0 and 0, 
respectively (KB = 60.0 µM, τB = 0.27). Additionally, both the cyclopropylamino analogue (19db) 
(KB = 1.93 µM, τB = 0.32) and cyclobutylamino analogue (19dc) (KB = 137 µM, τB = 0.39) lost their 
modulatory effect upon DA and instead behaved as agonists. 
4.3.4. 6-Phenyl substituted analogues. Converting the fused cyclohexane system of 1 to the 
corresponding 6-phenyl-substituted thiophene in the presence of 3-(trifluoromethyl)anilino was 
previously not tolerated.18 However, in the presence of 4-(N,N-diethylamino), 19ea showed 
improved functional affinity (KB = 0.90 µM) relative to 1  and was a NAM of DA efficacy. The 
cyclopropylamino analogue 19eb also maintained affinity and negative allosteric cooperativity (KB 
= 6.35 µM, α = 0.60, β = 0.43). Conversely, the cyclobutylamino analogue 19ec no longer 
negatively modulated the action of DA but instead also acted as a weak agonist (KB = 4.50 µM, τB = 
0.28). These data further demonstrate that the nature of the amine at the 4-position can dramatically 
affect the type of functional behaviour exerted by this scaffold at the D2R.  
4.3.5. 5-Cyclohexyl substituted analogues. Integration of a 5-cyclohexyl substituent into the 
scaffold of 1 was previously shown to abolish activity.18 In line with these data, the N,N-
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diethylamino analogue (19fa) was also inactive. However, despite this, analogues 19fb (KB = 11.6 
µM, β = 0.09) and 19fc (KB = 2.92 µM, β = 0.03, Figure 4E) were both NAMs of DA efficacy at the 
D2R. These data indicate that incorporation of a 5-cyclohexyl substituent may be favourable 
depending on the nature of substituents at the 2- and 4-positions. 
4.3.6. 6-Cyclohexyl substituted analogues. Modifying the thiophene with a cyclohexyl substituent at 
the 6-position of 1 maintained low µM affinity and negative allosteric cooperativity.18 This 
substituent changed observed pharmacology from negative modulation of DA efficacy (β) to 
negative modulation of DA affinity (α). However, we found that incorporating the cyclohexyl 
substituent into analogues devoid of the 2-morpholinomethyl moiety (19ga-c) abolished activity 
regardless of the nature of the 4-substituent.   
4.3.7. 5,6-Dimethyl substituted analogues. This structural modification in conjunction with the 4-(3-
(trifluoromethyl)anilino) group was previously shown to abolish activity at the D2R.18 In the 
presence of an N,N-diethylamino in the 4-position, however, 19ha maintained low µM affinity (KB 
= 19.5 µM) but failed to have any effects on DA binding and function, instead displaying agonism 
(τB = 0.24). Conversely, the cyclopropylamino analogue (19hb) was inactive in our functional 
assay, while the cyclobutylamino analogue (19hc) maintained low µM affinity and was a NAM of 
DA efficacy (KB = 2.88 µM, β = 0.13, Figure 4F).   
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Table 3 Functional parameters derived from cAMP BRET assay for analogues of 2 with 
modifications to the 5/6-fused system and 4-position  
 
# n R1 R2 R3 pKB (KB, µM)a LogτB (τB)b Log α (α)c Log β (β)d 
2 2 
 
  
5.72 ± 0.13 
(1.92) = -3.0 = 0 = -3.0 
19aa 1 
 
  
6.13 ± 0.14 
(0.74)  = 0 
-0.85 ± 0.07 
(0.14) 
19ab 1 
 
  
5.22 ± 0.14 
(6.01)  
-0.13 ± 0.11 
(0.75) 
-0.55 ± 0.06 
(0.28) 
19ac 1 
 
  
3.99 ± 0.50 
(102) 
-0.25 ± 0.29 
(0.57) = 0 = 0 
19ba 3 
 
  nd 
19bb 3 
 
  
5.53 ± 0.07 
(2.96)  = 0 
-1.30 ± 0.07 
(0.05) 
19bc 3 
 
  
6.04 ± 0.13 
(0.91)  = 0 
-1.22 ± 0.09 
(0.06) 
19ca 4 
 
  
4.84 ± 0.13 
(14.5) NSE = 0 -3.0 
19cb 4 
 
  
6.27 ± 0.18 
(0.53)  = 0 
-1.00 ± 0.11 
(0.10) 
19cc 4 
 
  
5.40 ± 0.26 
(3.98)  = 0 
-0.58 ± 0.09 
(0.26) 
19da - 
  
H 4.22 ± 0.33 (60.0) 
-0.57 ± 0.14 
(0.27) = -3.0 = 0 
19db - 
  
H 5.72 ± 0.22 (1.93) 
-0.47 ± 0.09 
(0.32) = -3.0 = 0 
19dc - 
  
H 3.89 ± 0.52 (137) 
-0.41 ± 0.31 
(0.39) = -3.0 = 0 
19ea - 
 
H 
 
6.04 ± 0.23 
(0.90)  = 0 = -3.0 
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19eb - 
 
H 
 
5.92 ± 0.17 
(6.35)  
-0.22 ± 0.10 
(0.60) 
-0.37 ± 0.05 
(0.43) 
19ec - 
 
H 
 
5.35 ± 0.24 
(4.50) 
0.55 ± 0.10 
(0.28) = 0 = 0 
19fa - 
  
H nd 
19fb - 
  
H 4.93 ± 0.16 (11.6)  = 0 
-1.04 ± 0.19 
(0.09) 
19fc - 
  
H 5.53 ± 0.13 (2.92)  = 0 
-1.55 ± 0.19 
(0.03) 
19ga - 
 
H 
 
nd 
19gb - 
 
H 
 
nd 
19gc - 
 
H 
 
nd 
19ha - 
 
CH3 CH3 
4.71 ± 0.30 
(19.5) 
-0.61 ± 0.11 
(0.24) = 0 = 0 
19hb - 
 
CH3 CH3 nd 
19hc - 
 
CH3 CH3 
5.54 ± 0.16 
(2.88)   
-0.90 ± 0.08 
(0.13) 
aEstimate of the negative logarithm of the equilibrium dissociation constant determined in an cAMP functional assay. 
bEstimate of the logarithm of the net cooperativity factor between the modulator and dopamine determined in an cAMP 
functional assay. cEstimate of the intrinsic efficacy of the modulator determined in an cAMP functional assay. nd = 
inactive at concentrations up to 100 µM. NSE – non-specific effect,  compound determined to inhibit forskolin-
stimulated cAMP accumulation in the absence of the D2R. Values represent the mean ± S.E.M. from at least three 
independent experiments performed in duplicate. 
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Fig. 4. Various aliphatic amino substituents at the 4-position can recover allosteric 
pharmacology. Most modifications to the 5- and 6-positions of the thienopyrimidine were 
previously found to be detrimental to the activity of the target compound. However, these activities 
can be recovered and even enhanced when using N,N-diethylamino, cyclopropylamino or 
cyclobutylamino substituents at the  4-position. (A) Fused cyclopentane with 4-(N,N-diethylamino) 
substituent (19aa, KB = 0.74 µM, β = 0.14). (B) Fused cycloheptane with 4-(cyclopropylamino) 
substituent (19bb, KB = 2.96 µM, β = 0.05). (C) Fused cycloheptane with 4-(cyclobutylamino) 
substituent (19bc, KB = 0.91 µM, β = 0.06). (D). Fused cyclooctane with 4-(cycloproylamino) 
substituent (19cb, KB = 0.53 µM, β = 0.10). (E) 5-Cyclohexyl with 4-(cyclobutylamino) substituent 
(19fc, KB = 2.92 µM, β = 0.03). (F) 5,6-Dimethyl with 4-(cyclobutylamino) substituent (19hc, KB = 
2.88 µM,  β = 0.13). All data used in these graphs are detailed in Table 3 and are presented as mean 
± SEM from three independent experiments performed in duplicate.   
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Our data reveal that relatively subtle structural changes can cause a change in pharmacology 
from that of a NAM to that of a weak D2R agonist. With two exceptions, the actions of the ligands 
described within this study are mediated through interaction with the D2R. The phenomenon 
whereby subtle modifications to a small molecule allosteric scaffold act to modulate modes of 
pharmacology, presumably via a change in receptor conformation, have been coined as “molecular 
switches”.29 This phenomenon has been documented for allosteric ligands targeting multiple GPCR 
and non-GPCR targets, including muscarinic acetylcholine receptors (mAChRs),30-32 as well as 
kinase33 and phospholipase34,35 allosteric ligands. Molecular switches have been reported to 
encompass a number of subtle structural changes, for example, stereochemistry, ring size and 
simple aryl substitution (i.e. fluoro vs methyl) to afford compounds with diverse pharmacology (e.g. 
positive and negative alloseric modulators, partial antagonists, and agonists). Indeed it is not 
surprising that such changes to allosteric ligands can cause dramatic changes in pharmacology 
given that similarly subtle changes to orthosteric ligands can convert agonists to antagonists. 
However, for those compounds that displayed agonism rather than the NAM activity of 1, the 
nature of this agonism i.e. whether it is non-competitive (allosteric) or competitive (orthosteric), 
cannot be conclusively confirmed due to their low D2R affinity. Thus it is not clear whether such 
compounds bind to the same allosteric site as 1, and are examples of molecular switching, or 
whether the relatively subtle structural changes investigated within this study confer the ability to 
engage the orthosteric site.18 Indeed, our recent paper proposed that the allosteric binding site of 1 
was in close proximity to the orthosteric site.  
In summary, it is clear that the nature of substituents at the thieno[2,3-d]pyrimidine 4-, 5- and 6-
positions play a crucial role in both binding affinity and functional activity (e.g. anilino (9a) and 
cyclohexylamino (9b) at the 4-position are not tolerated). However, other 6-membered substituents 
(morpholino (9d) and piperazino (10)) convert NAMs to agonists and competitive antagonists, 
respectively. Moreover, smaller acyclic and cyclic at the 4-position (N,N-diethylamino (2), 
cyclopropylamino (9f), cyclopropylmethylamino (9g) and cyclobutylamino (9h)) are tolerated, with 
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all compounds retaining modulatory activity as well as 9h showing a 10-fold increase in affinity. 
Decreasing the fused ring size whilst bearing the cyclobutylamino substituent (19ac) abolishes any 
negative modulatory effects, and instead confers agonism. However the N,N-diethylamino (19aa) 
and cyclopropylamino (19ab) counterparts retain negative modulatory action. Interestingly, 
increasing the ring size (cycloheptane (19bc), cyclooctane (19cc)) while bearing the 
cyclobutylamino substituent maintains negative modulatory action. However, introduction of the 
N,N-diethylamino substituent to the cycloheptane analogue (19ba) completely abolishes activity. 
Additionally, introduction of a phenyl ring to the 5-position in the presence of any amine converts 
all analogues (19da-c) to agonists. In most cases, a cyclohexyl substituent at this position appears 
favourable (19fb-c) as these compounds retain affinity and cooperativity, whereas an N,N-
diethylamino substituent (19fa) abolishes activity. A phenyl substituent at the 6-posititon, however, 
is tolerated in the presence of N,N-diethylamino (19ea) and cycloproylamino (19eb), yet, with 
cyclobutylamino (19ec), this yields an agonist. Installing a cyclohexyl moiety at the 6-position 
abolishes activity for 19ga-c, whereas the activity profile of analogues bearing a 5,6-dimethyl 
substituent are highly dependent on the amine present at the 4-position (N,N-diethylamino (19ha) = 
agonist, cyclopropylamino (19hb) = inactive, and cyclobutylamino (19hc) = NAM). All NAMs 
identified were modulators of agonist efficacy, whereby structural modifications did not confer 
modulation of agonist affinity.  
 
5. Conclusions 
In this study, we report the functional characterisation of a small library of structural analogues 
based on a thieno[2,3-d]pyrimidine scaffold that we have previously shown to act as D2R NAMs. 
The impact of structural modification was initially assessed with respect to the type of amine 
substituent at the 4-position in the presence of the 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-
d]pyrimidine moiety (series 1). Having identified favourable amines from series 1, we further 
extended our study to the analysis of various substituents in place of the 5/6-fused cyclohexane 
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system in conjunction with one of three selected amines (series 2) at the 4-position. While many of 
these derivatives maintained NAM activity, some, surprisingly acted as D2R agonists. It is not clear 
from the present data if this change in activity relates to a switch from an allosteric to an orthosteric 
mode of engagement or whether these compounds bind to the same allosteric site yet display 
distinct pharmacological effects. Future studies are needed to address this but such efforts are 
complicated by the relatively low affinity of these ligands. In the presence of a fused cyclohexane 
system, small cyclic aliphatic amines (cyclopropylamino, cyclobutylamino) were found to be vital 
for negative modulatory action. Two of the highest affinity NAMs to arise from this scaffold were 
identified, 9h (KB = 0.57 µM, fused cyclohexane moiety) and 19cb (KB = 0.53 µM, fused 
cyclopentane moiety), that contain cyclobutylamino and cyclopropylamino substituents, 
respectively. Conversely, larger heterocyclic substituents (morpholino) and acyclic amines (tert-
butylamino) conferred agonism and abolished modulatory activity (9d and 9i, respectively). In 
combination with a range of different substituents at the 5/6-positions, however, small 
cyclic/acyclic aliphatic amines gave a range of analogues with differential functional pharmacology, 
ranging from NAMs of DA efficacy, to agonists and compounds with no apparent functional 
activity. Taken together, this study demonstrates that the pharmacology of analogues functionalised 
at the 4-, 5-, and 6-positions of the thieno[2,3-d]pyrimidine core is difficult to predict, resulting in 
shallow SAR. Such observations are consistent with SAR studies of allosteric modulators of other 
GPCR targets, highlighting the challenges associated with GPCR allosteric ligand design.   
 
6. Experimental section 
6.1. General methods for chemistry 
Chemicals and solvents were purchased from standard suppliers and used without further 
purification. Davisil silica gel (40−63 µm) for flash column chromatography was supplied by Grace 
Davison Discovery Sciences (Victoria, Australia), and deuterated solvents were purchased from 
Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd., Victoria, 
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Australia). Reactions were monitored by thin layer chromatography on commercially available 
precoated aluminum-backed plates (Merck Kieselgel 60 F254). Visualization was by examination 
under UV light (254 and 366 nm). A solution of ninhydrin (in ethanol) was used to visualize 
primary and secondary amines. All organic extracts collected after aqueous workup procedures 
were dried over anhydrous Na2SO4 before gravity/vacuum filtering and evaporation to dryness. 
Organic solvents were evaporated in vacuo at ≤40 °C (water bath temperature). 1H NMR and 13C 
NMR spectra were recorded on a Bruker Avance Nanobay III 400 MHz Ultrashield Plus 
spectrometer at 400.13 and 100.62 MHz, respectively. Chemical shifts (δ) are recorded in parts per 
million (ppm) with reference to the chemical shift of the deuterated solvent. Coupling constants (J) 
are recorded in Hz, and the significant multiplicities described by singlet (s), doublet (d), triplet (t), 
quadruplet (q), broad (br), multiplet (m), doublet of doublets (dd), and doublet of triplets (dt). 
Spectra were assigned using appropriate COSY, distortionless enhanced polarization transfer 
(DEPT), HSQC, and HMBC sequences. All NMR experiments were performed in CDCl3 to permit 
comparison of the spectra of the various analogues. Experiments were performed in acetone-d6, 
DMSO-d6, or MeOH-d4 where selected analogues lacked solubility in CDCl3. LCMS experiments 
were run using one of two systems to verify reaction outcome and purity. System A was the default 
unless otherwise stated. System A consisted of the following: an Agilent 6100 series single quad 
coupled to an Agilent 1200 series HPLC instrument using the following buffers: buffer A, 0.1% 
formic acid in H2O; buffer B, 0.1% formic acid in MeCN. The following gradient was used with a 
Phenomenex Luna 3 µm C8(2) 15 mm × 4.6 mm column and a flow rate of 0.5 mL/min and total 
run time of 12 min: 0−4 min 95% buffer A and 5% buffer B, 4−7 min 0% buffer A and 100% buffer 
B, 7−12 min 95% buffer A and 5% buffer B. Mass spectra were acquired in positive and negative 
ion modes with a scan range of 0−1000 m/z at 5 V. UV detection was carried out at 254 nm. System 
B consisted of the following: an Agilent 6120 series single quad coupled to an Agilent 1260 series 
HPLC instrument. The following buffers were used; buffer A, 0.1% formic acid in H2O; buffer B, 
0.1% formic acid in MeCN. The following gradient was used with a Poroshell 120 EC-C18 50 mm 
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× 3.0 mm, 2.7 µm column and a flow rate of 0.5 mL/min and total run time of 5 min: 0−1 min 95% 
buffer A and 5% buffer B, from 1 to 2.5 min up to 0% buffer A and 100% buffer B, held at this 
composition until 3.8 min, 3.8−4 min 95% buffer A and 5% buffer B, held until 5 min at this 
composition. Mass spectra were acquired in positive and negative ion modes with a scan range of 
100−1000 m/z. UV detection was carried out at 214 and 254 nm. All retention times (tR) are quoted 
in minutes. System C: Analytical reverse-phase HPLC was performed on a Waters HPLC system 
coupled directly to a photodiode array detector and fitted with a Phenomenex Luna C8 (2) 100 Å 
column (150 mm × 4.6 mm, 5 µm) using a binary solvent system: solvent A, 0.1% TFA/H2O; 
solvent B, 0.1% TFA/80% CH3CN/H2O. Gradient elution was achieved using 100% solvent A to 
100% solvent B over 20 min at a flow rate of 1 mL/min. All compounds subjected to biological 
testing were found to be >95% pure by HPLC at two wavelengths (λ of 254 and 214 nm).  
 
6.2. General synthetic procedures.  
6.3. General procedure A for the Synthesis of 9a-j, 15a-b, 19aa-hc 
In a suitable microwave reaction vessel the required chloropyrimidine (1 equiv.) was taken up in i-
PrOH. To this was added the required amine (1.1 equiv.) and the mixture irradiated under stirring at 
120 ˚C for 1-2 h. Upon completion of the reaction, the mixture was directly purified using FCC to 
afford the compound. Similarly, any precipitate could be collected under vacuum and washed 
several time with cold i-PrOH to afford the desired compound. 
 
6.3.1. N-Phenyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (9a) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 105 mg of a white 
amorphous solid (84%). LCMS (m/z): 281.9 [M+H]+. HPLC: tR 6.244 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H15N3S requires 282.1071 [M+H]+; found 282.1059. 1H NMR (CDCl3) δ 
8.48 (s, 1H), 7.64 (dt, J = 8.8, 1.7 Hz, 2H), 7.41 – 7.34 (m, 2H), 7.17 – 7.10 (m, 2H), 3.06 (dd, J = 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
28 
 
8.1, 3.9 Hz, 2H), 2.85 (dd, J = 8.0, 3.9 Hz, 2H), 2.03 – 1.89 (m, 4H). 13C NMR (CDCl3) δ 166.3, 
155.0, 152.6, 138.5, 134.7, 129.1, 124.8, 124.0, 121.3, 116.6, 26.5, 25.5, 22.5, 22.4. 
 
 
6.3.2. N-Cyclohexyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (9b) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 115 mg of a beige 
amorphous solid (82%). LCMS (m/z): 288.2 [M+H]+. HPLC: tR 6.383 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H21N3S requires 288.1533 [M+H]+; found 288.1529. 1H NMR (CDCl3) δ 
8.35 (s, 1H), 4.23 – 4.12 (m, 1H), 2.91 (dd, J = 6.8, 5.1 Hz, 2H), 2.79 (dd, J = 8.1, 3.7 Hz, 2H), 2.12 
– 2.03 (m, 2H), 1.96 – 1.85 (m, 4H), 1.75 (ddd, J = 13.3, 8.8, 5.0 Hz, 2H), 1.69 – 1.61 (m, 1H), 1.55 
– 1.42 (m, 2H), 1.32 – 1.21 (m, 3H). 13C NMR (CDCl3) δ 165.3, 156.9, 153.3, 132.9, 125.5, 116.0, 
48.9, 33.3, 26.5, 25.8, 25.5, 24.8, 22.7, 22.6. 
 
6.5.3. 4-(Piperidin-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (9c) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 95.2 mg of a white 
amorphous solid (68%). LCMS (m/z): 274.1 [M+H]+. HPLC: tR 6.478 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H19N3S requires 224.1374 [M+H]+; found 274.1372. 1H NMR (CDCl3) δ 
8.51 (s, 1H), 3.36 – 3.28 (m, 4H), 2.96 – 2.91 (m, 2H), 2.90 – 2.85 (m, J = 6.3, 1.6 Hz, 2H), 1.97 – 
1.90 (m, 2H), 1.81 (ddd, J = 12.1, 5.9, 2.6 Hz, 2H), 1.77 – 1.71 (m, 4H), 1.69 – 1.62 (m, 2H). 13C 
NMR (CDCl3) δ 168.1, 162.9, 151.6, 134.4, 127.7, 121.5, 51.8, 26.7, 25.8, 25.7, 24.4, 23.1, 22.9. 
 
6.5.4. 4-(5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)morpholine (9d) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 161 mg of a white 
amorphous solid (88%). LCMS (m/z): 275.9 [M+H]+. HPLC: tR 5.179 min, >95% purity (214 & 
254 nm). HRMS (m/z): C14H17N3OS requires 275.1065 [M+H]+; found 275.1087.1H NMR (400 
MHz, CDCl3) δ 8.46 (s, 1H), 3.82 – 3.77 (m, 4H), 3.36 – 3.31 (m, 4H), 2.87 – 2.77 (m, 4H), 1.91 – 
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1.84 (m, 2H), 1.79 – 1.71 (m, 2H). 13C NMR (CDCl3) δ 168.39, 162.08, 151.46, 135.46, 126.9, 
121.4, 66.6, 51.1, 26.7, 25.8, 22.9, 22.8. 
  
 
6.5.5. 4-(Pyrrolidin-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (9e) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 109 mg of a white 
amorphous solid (82%). LCMS (m/z): 260.0 [M+H]+. HPLC: tR 5.270 min, >95% purity (214 & 
254 nm). HRMS (m/z): C14H17N3S requires 259.1112 [M+H]+; found 259.1138. 1H NMR (CDCl3) δ 
8.33 (s, 1H), 3.72 – 3.65 (m, 4H), 2.90 – 2.81 (m, 4H), 1.95 – 1.86 (m, 6H), 1.78 – 1.71 (m, 2H). 
13C NMR (CDCl3) δ 167.7, 158.8, 150.9, 132.2, 127.5, 117.9, 50.9, 29.2, 25.8, 25.5, 23.3, 22.8. 
 
6.5.6. N-Cyclopropyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (9f) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 105 mg of a white 
amorphous solid (87%). LCMS (m/z): 246.0 [M+H]+. HPLC: tR 4.864 min, >95% purity (214 & 
254 nm). HRMS (m/z): C13H15N3S requires 245.0954 [M+H]+; found 245.0981. 1H NMR (CDCl3) δ 
8.47 (s, 1H), 5.51 (s, 1H), 2.96 – 2.89 (m, 1H), 2.83 (td, J = 5.9, 1.9 Hz, 2H), 2.78 (td, J = 6.0, 1.9 
Hz, 2H), 1.95 – 1.83 (m, 4H), 0.95 – 0.90 (m, 2H), 0.61 – 0.57 (m, 2H). 13C NMR (CDCl3) δ 165.2, 
158.3, 153.1, 133.4, 125.3, 116.2, 26.4, 25.4, 23.9, 22.5, 22.4, 7.6. 
 
6.5.7. N-(Cyclopropylmethyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (9g) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 88 mg of a light yellow 
amorphous solid (85%). LCMS (m/z): 260.0 [M+H]+. HPLC: tR 5.519 min, >95% purity (214 & 
254 nm). HRMS (m/z): C14H17N3S requires 260.1215 [M+H]+; found 260.1216. 1H NMR (CDCl3) δ 
8.36 (s, 1H), 5.40 (s, 1H), 2.97 – 2.91 (m, J = 8.0, 4.1, 1.7 Hz, 1H), 2.82 – 2.78 (m, 2H), 1.98 – 1.85 
(m, 4H), 1.20 – 1.08 (m, 1H), 0.62 – 0.55 (m, 2H), 0.33 – 0.28 (m, 2H). 13C NMR (CDCl3) δ 
165.27, 157.40, 153.14, 133.1, 125.5, 116.1, 46.1, 26.4, 25.5, 22.7, 22.6, 10.8, 3.5. 
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6.5.8. N-Cyclobutyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (9h) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 101 mg of a white 
amorphous solid (88%). LCMS (m/z): 260.0 [M+H]+. HPLC: tR 5.612 min, >95% purity (214 & 
254 nm). HRMS (m/z): C14H17N3S requires 260.1213 [M+H]+; found 260.1213. 1H NMR (CDCl3) δ 
8.37 (s, 1H), 5.41 (d, J = 6.2 Hz, 1H), 4.76 – 4.64 (m, 1H), 2.93 (td, J = 5.9, 1.6 Hz, 2H), 2.81 (dd, J 
= 9.8, 3.7 Hz, 2H), 2.50 (dddd, J = 13.6, 7.7, 3.7, 2.7 Hz, 2H), 1.99 – 1.85 (m, 6H), 1.85 – 1.76 (m, 
2H). 13C NMR (CDCl3) δ 165.51, 156.55, 153.20, 133.26, 125.42, 115.9, 46.2, 31.8, 26.5, 25.5, 
22.7, 22.6, 15.4.  
 
6.5.9. N-(tert-Butyl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-amine (9i) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 114 mg of a white 
amorphous solid (85%). LCMS (m/z): 262.0 [M+H]+. HPLC: tR 4.623 min, >95% purity (214 & 
254 nm). HRMS (m/z): C14H19N3S requires 261.1312 [M+H]+; found 261.1294. 1H NMR (CDCl3) δ 
8.34 (s, 1H), 5.28 (s, 1H), 2.88 (td, J = 5.9, 1.6 Hz, 2H), 2.78 (dd, J = 9.8, 3.7 Hz, 2H), 1.95 – 1.82 
(m, 4H), 1.53 (s, 9H). 13C NMR (CDCl3) δ 165.1, 157.3, 152.6, 132.7, 125.2, 116.4, 52.3, 29.2, 
26.5, 25.5, 22.7, 22.5. 
 
6.5.10. tert-Butyl-4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazine-1-
carboxylate (9j) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 244 mg of a white 
amorphous solid (84%). LCMS (m/z): 375.2 [M+H]+. HPLC: tR 7.500 min, >95% purity (214 & 
254 nm). 1H NMR (CDCl3) δ 8.45 (s, 1H), 3.53 (dd, J = 6.1, 4.1 Hz, 4H), 3.30 – 3.25 (m, 4H), 2.82 
(ddd, J = 9.2, 7.8, 3.7 Hz, 4H), 1.90 – 1.83 (m, 2H), 1.77 – 1.69 (m, 2H), 1.41 (s, 9H). 13C NMR 
(CDCl3) δ 168.5, 162.3, 154.9, 151.6, 135.6, 127.0, 121.6, 80.1, 28.5, 26.7, 25.8, 23.1, 22.8. 
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6.5.11. 4-(Piperazin-1-yl)-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine (10) 
tert-Butyl-4-(5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4-yl)piperazine-1-carboxylate 
(163 mg, 435 µmol) was dissolved in DCM. To this solution was added trifluoroacetic acid (5.00 
mL, 65.3 mmol) and the reaction mixture was stirred at r.t. for 3 h. The solvents were evaporated 
and the residue the residue was taken up in H2O (20 mL) and added to a separating funnel. The 
aqueous solution was washed with Et2O (3 × 30 mL), and the aqueous phase made alkaline with the 
addition of 2 M NaOH solution. This phase was then extracted with DCM (3 × 30 mL) and the 
organic extracts collected and dried over anhydrous Na2SO4 to afford 115 mg of the corresponding 
amine free base as a white amorphous solid (96%). LCMS (m/z): 274.9 [M+H]+. HPLC: tR 4.623 
min, >95% purity (214 & 254 nm). HRMS (m/z): C14H18N3S requires 275.1334 [M+H]+; found 
275.1334. 1H NMR (CDCl3) δ 8.52 (s, 1H), 3.41 – 3.34 (m, 4H), 3.07 – 3.03 (m, 4H), 2.95 – 2.91 
(m, 2H), 2.90 – 2.85 (m, 2H), 2.05 (s, 1H), 1.97 – 1.90 (m, 2H), 1.84 – 1.78 (m, 2H). 13C NMR 
(CDCl3) δ 168.3, 162.5, 151.5, 135.0, 127.2, 121.4, 51.9, 45.7, 26.8, 25.8, 23.0, 22.8. 
 
6.5.12. N-Cyclopropylthieno[2,3-d]pyrimidin-4-amine (15a) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 77.1 mg of a white 
amorphous solid (76%). LCMS (m/z): 191.9 [M+H]+. HPLC: tR 3.290 min, >95% purity (214 & 
254 nm). HRMS (m/z): C9H9N3S requires 192.0587 [M+H]+; found 192.0590. 1H NMR (CDCl3) δ 
8.55 (s, 1H), 7.35 (d, J = 5.2 Hz, 1H), 7.27 (d, J = 6.0 Hz, 1H), 5.92 (s, 1H), 3.03 – 2.97 (m, 1H), 
0.99 – 0.93 (m, 2H), 0.74 – 0.68 (m, 2H). 13C NMR (CDCl3) δ 167.3, 158.6, 153.9, 122.8, 118.4, 
116.2, 24.6, 8.2. 
 
6.5.13. N-Cyclobutylthieno[2,3-d]pyrimidin-4-amine (15b) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 85.1 mg of a white 
amorphous solid (79%). LCMS (m/z): 206.0 [M+H]+. HPLC: tR 3.952 min, >95% purity (214 & 
254 nm). HRMS (m/z): C14H17N3S requires 206.0744 [M+H]+; found 206.0746. 1H NMR (CDCl3) δ 
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8.50 (s, 1H), 7.27 (d, J = 5.9 Hz, 1H), 7.17 (d, J = 6.0 Hz, 1H), 5.53 (d, J = 5.9 Hz, 1H), 4.81 – 4.71 
(m, 1H), 2.57 – 2.46 (m, 2H), 2.07 – 1.92 (m, 2H), 1.85 – 1.75 (m, 2H). 13C NMR (CDCl3) δ 166.7, 
156.3, 154.2, 123.0, 117.2, 116.1, 46.4, 31.7, 15.3. 
 
6.5.14. N,N-Diethyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-amine (19aa) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 115 mg of a white 
amorphous solid (78%). LCMS (m/z): 248.1 [M+H]+. HPLC: tR 5.295 min, >95% purity (214 & 
254 nm). HRMS (m/z): C13H17N3S requires 248.1217 [M+H]+; found 248.1216. 1H NMR (CDCl3) δ 
8.35 (s, 1H), 3.59 (q, J = 7.1 Hz, 4H), 3.06 – 2.99 (m, 2H), 2.94 (ddt, J = 8.2, 6.6, 1.8 Hz, 2H), 2.44 
– 2.34 (m, 2H), 1.19 (t, J = 7.0 Hz, 6H). 13C NMR (CDCl3) δ 173.3, 159.4, 151.3, 138.2, 136.0, 
116.0, 43.7, 32.4, 29.8, 28.1, 13.1. 
 
6.5.15. N-Cyclopropyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-amine (19ab) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 105 mg of a white 
amorphous solid (77%). LCMS (m/z): 232.1 [M+H]+. HPLC: tR 4.629 min, >95% purity (214 & 
254 nm). HRMS (m/z): C12H13N3S requires 232.0903 [M+H]+; found 232.0903. 1H NMR (CDCl3) δ 
8.49 (s, 1H), 5.28 (s, 1H), 2.98 (t, J = 7.2 Hz, 4H), 2.92 (td, J = 6.6, 3.7 Hz, 1H), 2.57 – 2.47 (m, 
2H), 0.97 – 0.91 (m, 2H), 0.64 – 0.58 (m, 2H). 13C NMR (CDCl3) δ 170.7, 157.7, 153.2, 138.9, 
134.2, 133.1, 29.5, 29.2, 27.9, 23.8, 7.6. 
 
6.5.16. N-Cyclobutyl-6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-amine (19ac) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 90.1 mg of a white 
amorphous solid (83%). LCMS (m/z): 246.1 [M+H]+. HPLC: tR 5.373 min, >95% purity (214 & 
254 nm). HRMS (m/z): C13H15N3S requires 246.0466 [M+H]+; found 246.0464. 1H NMR (CDCl3) δ 
8.37 (s, 1H), 5.16 (d, J = 6.7 Hz, 1H), 4.77 – 4.65 (m, 1H), 3.06 – 2.96 (m, 4H), 2.60 – 2.45 (m, 
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4H), 1.99 – 1.86 (m, 2H), 1.84 – 1.75 (m, 2H). 13C NMR (CDCl3) δ 155.8, 153.2, 138.6, 134.3, 
113.1, 45.9, 31.8, 29.5, 29.2, 27.9, 15.2. 
 
 
 
6.5.17. N,N-Diethyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-amine (19ba) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 99.4 mg of a white 
amorphous solid (86%). LCMS (m/z): 276.0 [M+H]+. HPLC: tR 6.323 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H21N3S requires 276.1526 [M+H]+; found 276.1529. 1H NMR (CDCl3) δ 
8.40 (s, 1H), 3.36 (q, J = 7.1 Hz, 4H), 2.98 – 2.93 (m, 2H), 2.82 – 2.78 (m, 2H), 1.87 – 1.80 (m, 
2H), 1.68 – 1.62 (m, 2H), 1.56 (ddd, J = 11.4, 6.0, 2.8 Hz, 2H), 1.03 (t, J = 7.1 Hz, 7H). 13C NMR 
(CDCl3) δ 166.3, 161.7, 150.9, 138.2, 132.6, 121.6, 44.5, 32.8, 30.4, 28.7, 27.6, 27.4, 12.3. 
 
6.5.18. N-Cyclopropyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-amine 
(19bb) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 101 mg of a white 
amorphous solid (88%). LCMS (m/z): 274.2 [M+H]+. HPLC: tR 5.709 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H19N3S requires 274.1374 [M+H]+; found 274.1372. 1H NMR (CDCl3) δ 
8.48 (s, 1H), 5.53 (s, 1H), 2.97 – 2.90 (m, J = 5.7, 3.4 Hz, 4H), 2.90 – 2.84 (m, 4H), 1.93 – 1.86 (m, 
2H), 1.82 (td, J = 11.7, 7.2 Hz, 2H), 0.97 – 0.89 (m, 2H), 0.64 – 0.57 (m, 2H). 13C NMR (CDCl3) δ 
164.2, 158.4, 152.8, 137.37, 130.2, 117.5, 30.48, 30.32, 29.0, 27.1, 26.4, 24.2, 7.7. 
 
6.5.19. N-Cyclobutyl-6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-d]pyrimidin-4-amine (19bc) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 100 mg of a white 
amorphous solid (88%). LCMS (m/z): 274.0 [M+H]+. HPLC: tR 5.908 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H19N3S requires 274.1371 [M+H]+; found 274.1372. 1H NMR (CDCl3) δ 
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8.35 (s, 1H), 5.40 (d, J = 6.3 Hz, 1H), 4.74 – 4.63 (m, 1H), 3.04 – 2.99 (m, 2H), 2.87 (dd, J = 6.7, 
4.3 Hz, 2H), 2.55 – 2.45 (m, 2H), 2.03 – 1.69 (m, 10H). 13C NMR (CDCl3) δ 164.4, 156.5, 152.8, 
136.9, 130.2, 117.1, 46.4, 31.8, 30.4, 30.4, 28.9, 27.2, 26.4, 22.5, 15.5. 
 
 
6.5.20. N,N-Diethyl-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4-amine (19ca) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 113 mg of a white 
amorphous solid (79%). LCMS (m/z): 290.2 [M+H]+. HPLC: tR 7.076 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H23N3S requires 290.1689 [M+H]+; found 290.1685. 1H NMR (CDCl3) δ 
8.57 (s, 1H), 3.43 (q, J = 7.1 Hz, 4H), 3.05 – 3.01 (m, 2H), 2.93 – 2.89 (m, 2H), 1.78 – 1.71 (m, 
2H), 1.57 (tt, J = 8.4, 6.2 Hz, 2H), 1.49 – 1.42 (m, 2H), 1.16 – 1.11 (m, J = 8.3, 3.6 Hz, 2H), 1.09 (t, 
J = 7.1 Hz, 6H). 13C NMR (CDCl3) δ 168.0, 162.4, 151.2, 138.5, 129.8, 121.6, 45.5, 31.8, 31.2, 
27.9, 26.2, 25.4, 24.6, 12.3. 
 
6.5.21. N-Cyclopropyl-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4-amine 
(19cb) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 75.2 mg of a white 
amorphous solid (77%). LCMS (m/z): 274.2 [M+H]+. HPLC: tR 5.709 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H19N3S requires 274.1374 [M+H]+; found 274.1372. 1H NMR (CDCl3) δ 
8.52 (d, J = 3.2 Hz, 1H), 5.57 (s, 1H), 3.01 – 2.94 (m, 1H), 2.87 (dd, J = 12.3, 5.1 Hz, 4H), 1.75 – 
1.66 (m, 4H), 1.57 – 1.48 (m, 2H), 1.38 – 1.27 (m, 2H), 0.99 – 0.92 (m, 2H), 0.62 – 0.57 (m, 2H). 
13C NMR (CDCl3) δ 164.9, 157.9, 152.9, 136.6, 127.5, 116.3, 31.6, 29.9, 27.8, 26.1, 25.2, 23.9, 7.7. 
 
6.5.22. N-Cyclobutyl-5,6,7,8,9,10-hexahydrocycloocta[4,5]thieno[2,3-d]pyrimidin-4-amine (19cc) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 122 mg of a white 
amorphous solid (86%). LCMS (m/z): 288.2 [M+H]+. HPLC: tR 6.266 min, >95% purity (214 & 
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254 nm). HRMS (m/z): C16H21N3S requires 288.1531 [M+H]+; found 288.1531. 1H NMR (CDCl3) δ 
8.39 (s, 1H), 5.48 (d, J = 6.6 Hz, 1H), 4.80 – 4.67 (m, 1H), 2.95 – 2.90 (m, 2H), 2.90 – 2.85 (m, 
2H), 2.57 – 2.47 (m, 2H), 1.98 – 1.86 (m, 2H), 1.86 – 1.74 (m, 4H), 1.74 – 1.65 (m, 2H), 1.57 – 
1.49 (m, 2H), 1.35 (dt, J = 10.7, 6.1 Hz, 2H). 13C NMR (CDCl3) δ 165.1, 156.1, 152.8, 136.3, 
127.5, 115.9, 46.1, 31.8, 31.6, 29.9, 27.8, 26.1, 25.2, 15.3. 
 
6.5.23. N,N-Diethyl-5-phenylthieno[2,3-d]pyrimidin-4-amine (19da) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 94.1 mg of a white 
amorphous solid (86%). LCMS (m/z): 283.9 [M+H]+. HPLC: tR 6.1389 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H17N3S requires 284.1213 [M+H]+; found 284.1216. 1H NMR (CDCl3) δ 
8.55 (s, 1H), 7.44 – 7.38 (m, 4H), 7.37 – 7.32 (m, 1H), 7.18 (s, 1H), 3.16 (q, J = 7.1 Hz, 4H), 0.89 
(t, J = 7.1 Hz, 6H). 13C NMR (CDCl3) δ 170.1, 160.9, 152.11, 136.8, 136.4, 128.4, 128.1, 127.6, 
120.5, 115.6, 43.7, 12.3. 
 
6.5.24. N-Cyclopropyl-5-phenylthieno[2,3-d]pyrimidin-4-amine (19db) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 98.3 mg of a white 
amorphous solid (86%). LCMS (m/z): 267.9 [M+H]+. HPLC: tR 5.308 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H13N3S requires 268.0830 [M+H]+; found 268.0903. 1H NMR (CDCl3) δ 
8.60 (s, 1H), 7.51 – 7.47 (m, 3H), 7.43 – 7.38 (m, 2H), 7.07 (s, 1H), 5.11 (s, 1H), 2.87 – 2.80 (m, 
1H), 0.80 – 0.74 (m, 2H), 0.29 – 0.24 (m, 2H). 13C NMR (CDCl3) δ 166.9, 158.6, 154.4, 136.2, 
134.7, 129.3, 129.1, 128.9, 120.5, 114.27, 23.7, 7.3. 
 
6.5.25. N-Cyclobutyl-5-phenylthieno[2,3-d]pyrimidin-4-amine (19dc) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 85.1 mg of a white 
amorphous solid (75%). LCMS (m/z): 281.9 [M+H]+. HPLC: tR 6.183 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H15N3S requires 282.1059 [M+H]+; found 282.1059. 1H NMR (CDCl3) δ 
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8.48 (s, 1H), 7.54 – 7.49 (m, 5H), 7.46 (dd, J = 6.7, 2.7 Hz, 2H), 7.07 (s, 1H), 5.10 (d, J = 5.5 Hz, 
1H), 4.62 – 4.50 (m, 1H), 2.37 – 2.27 (m, 2H), 1.73 – 1.59 (m, 2H), 1.57 – 1.44 (m, 2H). 13C NMR 
(CDCl3) δ 166.9, 156.4, 154.2, 136.2, 134.7, 129.4, 128.89, 128.7, 120.0, 113.9, 45.7, 31.2, 15.2. 
 
 
 
6.5.26. N,N-Diethyl-6-phenylthieno[2,3-d]pyrimidin-4-amine (19ea) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 96.8 mg of a white 
amorphous solid (84%). LCMS (m/z): 284.0 [M+H]+. HPLC: tR 6.080 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H17N3S requires 284.1213 [M+H]+; found 284.1216. 1H NMR (CDCl3) δ 
8.41 (s, 1H), 7.65 – 7.61 (m, 2H), 7.48 (s, 1H), 7.45 – 7.40 (m, 2H), 7.37 – 7.32 (m, 1H), 3.79 (q, J 
= 7.1 Hz, 4H), 1.36 (t, J = 7.1 Hz, 6H). 13C NMR (CDCl3) δ 168.9, 156.9, 153.2, 138.1, 134.1, 
129.2, 128.4, 126.3, 116.8, 116.4, 44.2, 13.4. 
 
6.5.27. N-Cyclopropyl-6-phenylthieno[2,3-d]pyrimidin-4-amine (19eb) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 99.1 mg of a white 
amorphous solid (90%). LCMS (m/z): 267.9 [M+H]+. HPLC: tR 5.407 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H13N3S requires 268.0830 [M+H]+; found 268.0903. 1H NMR (401 
MHz, CDCl3) δ 8.53 (s, 1H), 7.65 – 7.61 (m, 1H), 7.49 (s, 1H), 7.44 – 7.38 (m, 1H), 7.37 – 7.32 (m, 
1H), 5.79 (s, 1H), 3.06 – 2.99 (m, 1H), 1.01 – 0.95 (m, 1H), 0.74 – 0.70 (m, 1H). 13C NMR (101 
MHz, CDCl3) δ 166.8, 158.2, 153.9, 140.7, 133.6, 129.2, 128.7, 126.4, 117.7, 113.3, 24.6, 8.2.  
 
6.5.28. N-Cyclobutyl-6-phenylthieno[2,3-d]pyrimidin-4-amine (19ec) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 108 mg of a white 
amorphous solid (92%). LCMS (m/z): 281.9 [M+H]+. HPLC: tR 5.940 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H15N3S requires 282.1058 [M+H]+; found 282.1059. 1H NMR (CDCl3) δ 
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8.48 (s, 1H), 7.65 – 7.62 (m, 2H), 7.45 – 7.39 (m, 2H), 7.37 – 7.31 (m, 2H), 5.47 (d, J = 7.2 Hz, 
1H), 4.83 – 4.72 (m, 1H), 2.63 – 2.41 (m, 2H), 2.07 – 1.95 (m, 2H), 1.87 – 1.77 (m, 2H). 13C NMR 
(CDCl3) δ 166.1, 155.9, 154.1, 140.9, 133.6, 129.2, 128.7, 126.3, 117.6, 112.5, 46.4, 31.7, 15.3. 
 
 
 
6.5.29. 5-Cyclohexyl-N,N-diethylthieno[2,3-d]pyrimidin-4-amine (19fa) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 115 mg of a white 
amorphous solid (81%). LCMS (m/z): 290.2 [M+H]+. HPLC: tR 7.189 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H23N3S requires 290.1689 [M+H]+; found 290.1685. 1H NMR (CDCl3) δ 
8.58 (s, 1H), 7.02 (s, 1H), 3.47 (q, J = 7.1 Hz, 1H), 3.17 – 3.06 (m, J = 2.9 Hz, 1H), 1.98 (dd, J = 
12.7, 1.3 Hz, 1H), 1.89 – 1.82 (m, 1H), 1.81 – 1.73 (m, 1H), 1.48 – 1.20 (m, 1H), 1.13 (t, J = 7.1 
Hz, 1H). 13C NMR (CDCl3) δ 169.8, 163.3, 151.6, 141.6, 119.9, 117.3, 45.0, 38.4, 34.8, 26.9, 26.2, 
12.4. 
 
6.5.30. 5-Cyclohexyl-N-cyclopropylthieno[2,3-d]pyrimidin-4-amine (19fb) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 87.8 mg of a white 
amorphous solid (88%). LCMS (m/z): 274.2 [M+H]+. HPLC: tR 6.073 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H15N3S requires 274.1375 [M+H]+; found 274.1372. 1H NMR (CDCl3) δ 
8.55 (s, 1H), 6.87 (s, 1H), 5.57 (s, 1H), 3.07 – 2.99 (m, 1H), 2.59 (dd, J = 13.5, 5.5 Hz, 1H), 2.06 (t, 
J = 11.0 Hz, 2H), 1.95 (t, J = 10.5 Hz, 2H), 1.83 (d, J = 12.7 Hz, 1H), 1.50 – 1.38 (m, 4H), 1.30 
(ddd, J = 13.7, 12.5, 4.9 Hz, 1H), 1.01 – 0.95 (m, 2H), 0.63 – 0.56 (m, 2H). 13C NMR (CDCl3) δ 
167.7, 158.6, 153.5, 139.7, 115.6, 115.3, 40.9, 33.9, 26.7, 25.9, 24.1, 7.7. 
 
6.5.31. N-Cyclobutyl-5-cyclohexylthieno[2,3-d]pyrimidin-4-amine (19fc) 
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General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 115 mg of a white 
amorphous solid (81%). LCMS (m/z): 288.2 [M+H]+. HPLC: tR 6.820 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H21N3S requires 288.1531 [M+H]+; found 288.1529. 1H NMR (CDCl3) δ 
8.43 (s, 1H), 6.85 (s, 1H), 5.51 (d, J = 6.3 Hz, 1H), 4.79 – 4.69 (m, 1H), 2.74 – 2.66 (m, 1H), 2.60 – 
2.50 (m, 2H), 2.15 (d, J = 8.2 Hz, 2H), 2.02 – 1.90 (m, 4H), 1.91 – 1.81 (m, 5H), 1.53 – 1.40 (m, 
5H), 1.34 (ddd, J = 12.5, 8.2, 3.5 Hz, 1H). 13C NMR (CDCl3) δ 167.8, 156.6, 153.5, 139.8, 115.2, 
46.2, 41.0, 33.9, 31.7, 26.8, 26.0, 15.4. 
 
6.5.32. 6-Cyclohexyl-N,N-diethylthieno[2,3-d]pyrimidin-4-amine (19ga) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 113 mg of a white 
amorphous solid (91%). LCMS (m/z): 290.0 [M+H]+. HPLC: tR 6.559 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H23N3S requires 290.1683 [M+H]+; found 290.1685. 1H NMR (CDCl3) δ 
8.37 (s, 1H), 6.96 (d, J = 1.0 Hz, 1H), 3.73 (q, J = 7.1 Hz, 4H), 2.83 (tt, J = 11.2, 3.5 Hz, 1H), 2.10 
– 2.04 (m, 2H), 1.89 – 1.82 (m, 2H), 1.79 – 1.71 (m, 1H), 1.55 – 1.35 (m, 4H), 1.32 (t, J = 7.1 Hz, 
6H), 1.30 – 1.19 (m, 1H). 13C NMR (CDCl3) δ 167.9, 156.6, 152.5, 146.9, 115.4, 115.3, 44.07, 40.3, 
35.1, 26.4, 25.9, 13.6. 
 
6.5.33. 6-Cyclohexyl-N-cyclopropylthieno[2,3-d]pyrimidin-4-amine (19gb) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 84.8 mg of a white 
amorphous solid (87%). LCMS (m/z): 274.0 [M+H]+. HPLC: tR 5.986 min, >95% purity (214 & 
254 nm). HRMS (m/z): C15H19N3S requires 274.1369 [M+H]+; found 274.1372. 1H NMR (CDCl3) δ 
8.49 (s, 1H), 6.94 (s, 1H), 5.63 (s, 1H), 2.97 (qd, J = 6.7, 3.6 Hz, 1H), 2.81 (td, J = 10.9, 3.2 Hz, 
1H), 2.06 (d, J = 10.6 Hz, 2H), 1.87 – 1.81 (m, 2H), 1.74 (d, J = 12.7 Hz, 1H), 1.52 – 1.33 (m, 4H), 
1.31 – 1.20 (m, 1H), 0.97 – 0.91 (m, 2H), 0.70 – 0.64 (m, 2H). 13C NMR (CDCl3) δ 157.65, 153.3, 
149.7, 116.5, 111.8, 40.2, 35.01, 26.3, 25.9, 24.5, 8.15. 
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6.5.34. N-Cyclobutyl-6-cyclohexylthieno[2,3-d]pyrimidin-4-amine (19gc) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 101 mg of a white 
amorphous solid (88%). LCMS (m/z): 288.0 [M+H]+. HPLC: tR 6.377 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H21N3S requires 288.1528 [M+H]+; found 288.1529. 1H NMR (CDCl3) δ 
8.43 (s, 1H), 6.80 (d, J = 1.0 Hz, 1H), 5.31 (d, J = 7.2 Hz, 1H), 4.80 – 4.67 (m, 1H), 2.86 – 2.77 (m, 
1H), 2.55 – 2.45 (m, 2H), 2.11 – 2.04 (m, 2H), 2.03 – 1.91 (m, 2H), 1.89 – 1.71 (m, 5H), 1.53 – 
1.33 (m, 4H), 1.32 – 1.20 (m, 1H). 13C NMR (CDCl3) δ 165.36, 155.53, 153.38, 149.88, 116.4, 
111.1, 46.3, 40.2, 35.0, 31.8, 26.4, 25.9, 15.3. 
6.5.35. N,N-Diethyl-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine (19ha) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 82.3 mg of a white 
amorphous solid (71%). LCMS (m/z): 236.0 [M+H]+. HPLC: tR 5.322 min, >95% purity (214 & 
254 nm). HRMS (m/z): C12H17N3S requires 236.1212 [M+H]+; found 236.1216. 1H NMR (CDCl3) δ 
8.50 (s, 1H), 3.46 (q, J = 7.1 Hz, 4H), 2.43 (d, J = 0.8 Hz, 3H), 2.41 (d, J = 0.7 Hz, 3H), 1.12 (t, J = 
7.1 Hz, 6H). 13C NMR (CDCl3) δ 167.2, 162.0, 151.1, 131.3, 124.9, 122.3, 44.8, 13.9, 13.7, 12.3. 
 
6.5.36. N-Cyclopropyl-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine (19hb) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 101 mg of a white 
amorphous solid (93%). LCMS (m/z): 220.1 [M+H]+. HPLC: tR 5.322 min, >95% purity (214 & 
254 nm). HRMS (m/z): C11H13N3S requires 220.0898 [M+H]+; found 220.0903. 1H NMR (CDCl3) δ 
8.49 (s, 1H), 5.65 (s, 1H), 2.98 – 2.91 (m, 1H), 2.41 (s, 6H), 0.97 – 0.91 (m, 2H), 0.63 – 0.58 (m, 
2H). 13C NMR (CDCl3) δ 164.6, 158.4, 153.2, 130.2, 122.9, 117.2, 24.1, 14.5, 13.5, 7.7. 
 
6.5.37. N-Cyclobutyl-5,6-dimethylthieno[2,3-d]pyrimidin-4-amine (19hc) 
General procedure A. Purification by FCC (eluent, 1:1 EtOAc/PE) afforded 85.5 mg of a white 
amorphous solid (73%). LCMS (m/z): 234.0 [M+H]+. HPLC: tR 5.940 min, >95% purity (214 & 
254 nm). HRMS (m/z): C16H15N3S requires 234.1056 [M+H]+; found 234.1059. 1H NMR (CDCl3) δ 
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8.37 (s, 1H), 5.55 (d, J = 5.9 Hz, 1H), 4.81 – 4.59 (m, 1H), 2.54 – 2.48 (m, 2H), 2.46 (s, 3H), 2.41 
(d, J = 0.6 Hz, 3H), 1.98 – 1.86 (m, 2H), 1.86 – 1.76 (m, 2H). 13C NMR (CDCl3) δ 164.8, 156.5, 
153.1, 129.8, 123.0, 116.8, 46.2, 31.8, 15.4, 14.5, 13.5. 
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6.6. Pharmacological Characterisation 
6.6.1. Materials 
Dulbecco’s modified Eagle’s medium, Flp-In CHO cells, and hygromycin B were purchased from 
Invitrogen (Carlsbad, CA). Fetal bovine serum (FBS) was purchased from ThermoTrace 
(Melbourne, VIC, Australia). All other reagents were purchased from Sigma Aldrich (St. Louis, 
MO). 
 
6.6.2. Cell culture and transfection for cAMP assay 
FlpIn CHO cells stably expressing the human dopamine D2L receptor (or WT FlpIn CHO cells for 
off-target screening assay) were maintained in DMEM supplemented with 5% foetal calf serum 
(FBS) and 0.2 mg/mL hygromycin at 37 °C in a humidified incubator supplied with 5% CO2.  
 
6.6.3. cAMP measurement (interaction & off-target assay) 
The cellular cAMP levels were measured with the CAMYEL BRET-based biosensor for cAMP.26 
One day after transfection, cells were trypsinised and seeded in white 96-well microplates. The cells 
were then cultured for an additional day, rinsed twice with Hank's Balanced Salt Solution (HBSS) 
and were then incubated in fresh HBSS. The Renilla luciferase (RLuc) substrate coelenterazine-h 
was added to reach a final concentration of 5 µM.  
 
Interaction assay: FlpIn CHO cells stably expressing the human dopamine D2L receptor were 
stimulated with dopamine in the presence of 10 µM forskolin (final concentration). For the 
antagonism assay, the allosteric antagonists were added 30 min prior to stimulation. The BRET 
signals were measured using a BMG Lumistar counter 30 min after stimulation. The BRET signal 
(BRET ratio) was determined by calculating the ratio of the light emitted at 535 ± 30 nm (YFP) to 
the light emitted at 475 ± 30 nm (RLuc). 
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 Off-target assay using non-hD2LR-expressing Flp-In CHO cells: The allosteric antagonists (1-100 
µM), and dopamine (10 µM) were added 30 min prior to stimulation in the presence or absence of 
10 µM forskolin (final concentration). The BRET signals were measured using a BMG Lumistar 
counter 30 min after stimulation. The BRET signal (BRET ratio) was determined by calculating the 
ratio of the light emitted at 535 ± 30 nm (YFP) to the light emitted at 475 ± 30 nm (RLuc). 
 
6.6.4. Data analysis 
Computerized nonlinear regression, statistical analyses and simulations were performed using Prism 
6.0 (GraphPad Prism 6.0b Software, San Diego, CA).  
 
6.6.5. Analysis of functional data 
All concentration-response data were fitted to the following modified four-parameter Hill equation 
to derive potency estimates.36  
 
 =  + 	
.[][]	     (1) 
 
where E is the effect of the system, nH is the Hill slope and EC50 is the concentration of agonist [A] 
that gives the midpoint response between basal and maximal effect of dopamine or other agonists 
(Emax), which are the lower and upper asymptotes of the response, respectively. 
To determine the mode of interaction of 1 and analogues of 1 at the D2R in relation to the agonist 
dopamine, data were fit to both a competitive and allosteric model and the best fit compared 
statistically. A logistic equation of competitive agonist-antagonist interaction was globally fitted to 
data from functional experiments measuring the interaction between dopamine and all analogues of 
1:  
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Where s represents the Schild slope for the antagonist and pA2 represents the negative logarithm of 
the molar concentration of antagonist that makes it necessary to double the concentration of agonist 
needed to elicit the original submaximal response obtained in the absence of antagonist. The same 
data describing the interaction between all analogues of 1 and dopamine were also analyzed using a 
complete operational model of allosterism and agonism according to equation 5:37 
 
 
 = 	
:7[];2	=>[]:2[];	7[];2;7;2;7[]=[][]:7[];2=>[]:2[];7    (3)
 
 
Where Em is the maximum possible cellular response, [A] and [B] are the concentrations of 
orthosteric and allosteric ligands, respectively, KA and KB are the equilibrium dissociation constant 
of the orthosteric and allosteric ligands, respectively, τA and τB (constrained to -100) are operational 
measures of orthosteric and allosteric ligand efficacy (which incorporate both signal efficiency and 
receptor density), respectively, α is the binding cooperativity parameter between the orthosteric and 
allosteric ligand, and β denotes the magnitude of the allosteric effect of the modulator on the 
efficacy of the orthosteric agonist. KA was constrained to 617 nM, and represents a value of 
functional affinity determined by an operational model of agonism applied to concentration-
response data of dopamine in the presence of increasing concentrations of the alkylating agent 
phenoxybenzamine. For compounds that caused a limited rightward shift of the dopamine dose-
response curve but no decrease in Emax, data were fit using an operational model of allosterism 
where Logβ was constrained to 0 to represent neutral cooperativity with dopamine efficacy. For 
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compounds that produced an unlimited decrease in the maximal response of dopamine Logβ was 
constrained to -3.   
 For each of the compounds the two equations (models) were then compared for their fit 
using an extra-sum-of-squares F test. All of the data points and values shown in the figures and 
tables are the mean ± S.E.M. of at least three separate experiments performed in duplicate unless 
otherwise stated.  
 
Associated Content 
Supporting Information: 
1H & 13C NMR spectra are included for all compounds depicted in Figures 3 & 4 (9d, 9f, 10, 15b, 
19aa, 19bb, 19bc, 19cb, 19hc), together with compounds found to non-specifically inhibit cAMP 
accumulation (9c & 19ca). Reverse-phase analytical HPLC traces and high-resolution mass spectra 
are included for key compounds highlighted in the TOC graphic (9d, 9h, 9i, 19fc). 
 
Author information 
Corresponding Authors 
*B.C.: phone, +61 9903 9556; e-mail, ben.capuano@monash.edu 
*J.R.L.: phone, +61 3 9903 9095; e-mail, rob.lane@nottingham.ac.uk 
 
Author Contributions 
Notes The authors declare no competing financial interest. 
 
Acknowledgments  
This research was supported by a National Health and Medical Research Council (NHMRC) Project 
Grant Number APP1049564.  
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
45 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
46 
 
Abbreviation list 
cAMP, cyclic adenosine monophosphate; D2R, dopamine D2 receptor; D3R, dopamine D3 receptor; 
dopamine, DA; GPCR, G protein-coupled receptor; EPS, extrapyramidal symptoms; NAM, 
negative allosteric modulator; PAM, positive allosteric modulator; VLS, virtual ligand screening; 
SAR, structure-activity relationship; CHO, chinese hamster ovary; BRET, bioluminescence 
resonance energy transfer; FBS, foetal bovine serum; HBSS, hank's balanced salt solution; SEM, 
standard error of mean; DMF, N,N-dimethylformamide, POCl3, phosphorus oxychloride; i-PrOH, 
isopropyl alcohol; EtOAc, ethyl acetate; DCM, dichloromethane; MWI, microwave irradiation. 
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Highlights 
• Structural changes furnished allosteric fragment-like cores with improved ligand efficiency 
• Substituents at the thieno[2,3-d]pyrimidine core are crucial for binding and function at the D2R 
• Subtle variations cause a change in pharmacology from that of a D2R NAM to that of a weak D2R 
agonist 
